Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
← catalyst calendarNCT06760637 · readout in 866 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,035actual
Sites
463
Countries
Argentina, Australia, Belgium +27
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-06 | actual | When the study began enrolling |
| Primary completion | 2029-01-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2037-12-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer
Interventions
- Drug: PF-07220060
- Drug: letrozole
- Drug: abemaciclib
- Drug: palbociclib
- Drug: ribociclib
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS) by BICR
measured From the date of randomization until disease progression or death due to any cause (up to approximately 4 years)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed